Pharmaceuticals

"Pharmaceuticals" Main

Latest Morning Briefing Stories

Doctors’ Lesson for Drug Industry: Abortion Wars Are Dangerous to Ignore

KFF Health News Original

The American Medical Association ducked the abortion issue for years and now sees its members’ professional opinions second-guessed by lawmakers and judges. PhRMA is following the same playbook.

Watch: Rulings on Abortion Pill Have Far-Reaching Repercussions

KFF Health News Original

Sarah Varney, a senior correspondent for KHN, joins Ali Rogin of PBS NewsHour to discuss the ruling by a federal judge in Texas that threatens nationwide access to the widely used abortion drug mifepristone, and a separate ruling in Washington state that reached the opposite conclusion.

Gov. Newsom Wanted California to Cut Ties With Walgreens. Then Federal Law Got in the Way.

KFF Health News Original

Gov. Gavin Newsom declared that California would cut ties with Walgreens after the company said it would not distribute abortion pills in some states. But federal rules make it difficult for the state to unwind its Medicaid prescription drug agreement, which paid Walgreens $1.5 billion last year.

States Try to Obscure Execution Details as Drugmakers Hinder Lethal Injection

KFF Health News Original

Pharmaceutical companies have put the brakes on many states’ ability to execute prisoners using lethal injections. Lacking alternatives, states are trying to keep the public from learning details about how they carry out executions.

Sen. Sanders Shows Fire, but Seeks Modest Goals, in His Debut Drug Hearing as Health Chair

KFF Health News Original

The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn’t clear whether Sanders will succeed in even that, but he has put affordability front and center.

KFF Health News' 'What the Health?': The Policy, and Politics, of Medicare Advantage

Podcast

Medicare Advantage, the private plan alternative to traditional Medicare, is embroiled in a growing controversy over whether insurers are being overpaid and what it would mean to reduce those payments. Meanwhile, even as maternal mortality in the U.S. continues to rise, providers of care to pregnant women say they’re leaving states with abortion bans that prevent them from treating pregnancy complications. Margot Sanger-Katz of The New York Times, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s chief Washington correspondent Julie Rovner to discuss these issues and more.

Judge Signals He Could Rule to Halt Sales of Common Abortion Pill

KFF Health News Original

A U.S. District Court case is being widely followed because the judge’s decision could overturn the FDA’s approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.

¿Ayudan las nuevas guías sobre opioides a los pacientes con dolor crónico?

KFF Health News Original

Las recomendaciones dejaron a muchos pacientes lidiando con las consecuencias para la salud mental y física de la reducción rápida de la dosis o la suspensión abrupta de los medicamentos que habían estado tomando durante años, lo que conlleva riesgos de abstinencia, depresión e incluso suicidio.

New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?

KFF Health News Original

In November, the Centers for Disease Control and Prevention released new guidelines for prescribing opioids for pain, allowing physicians more flexibility. But doctors, patients, and advocates wonder if the updated standards will be too little, too late to help chronic pain patients in a country still focused on fighting the ongoing opioid crisis.

KFF Health News' 'What the Health?': Biden Budget Touches All the Bases

Podcast

Very little in the proposed budget released by the Biden administration is likely to become law, particularly with Republicans in charge of the U.S. House. Still, the document is an important statement of the president’s policy priorities, and it’s clear health programs are among those he feels are important. Meanwhile, five women who were denied abortions when their pregnancies threatened their lives are suing Texas. Shefali Luthra of The 19th, Victoria Knight of Axios, and Margot Sanger-Katz of The New York Times join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Harris Meyer, who reported and wrote the two latest KHN-NPR “Bill of the Month” features. Both were about families facing unexpected bills following childbirth.

Decisión de Eli Lilly de bajar el precio de su insulina logrará cambios históricos en los costos

KFF Health News Original

Expertos en precios de medicamentos celebraron la noticia de Eli Lilly y otros esfuerzos. Y estas otras iniciativas para llevar al mercado insulina de menor costo, a su vez, presionarían a Eli Lilly para que mantuviera sus precios bajos.

Eli Lilly Slashed Insulin Prices. This Starts a Race to the Bottom.

KFF Health News Original

Eli Lilly’s news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.